A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis

Brett Morrison, Jennifer L. Lachey, Leigh C. Warsing, Beverlie L. Ting, Abigail E. Pullen, Kathryn W. Underwood, Ravindra Kumar, Dianne Sako, Asya Grinberg, Vicki Wong, Elizabeth Ann Colantuoni, Jasbir S. Seehra, Kathryn Rae Wagner

Research output: Contribution to journalArticle

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurologic disease characterized by progressive weakness that results in death within a few years of onset by respiratory failure. Myostatin is a member of the TGF-β superfamily that is predominantly expressed in muscle and acts as a negative regulator of muscle growth. Attenuating myostatin has previously been shown to produce increased muscle mass and strength in normal and disease animal models. In this study, a mouse model of ALS (SOD1G93A transgenic mice) was treated with a soluble activin receptor, type IIB (ActRIIB.mFc) which is a putative endogenous signaling receptor for myostatin in addition to other ligands of the TGF-β superfamily. ActRIIB.mFc treatment produces a delay in the onset of weakness, an increase in body weight and grip strength, and an enlargement of muscle size whether initiated pre-symptomatically or after symptom onset. Treatment with ActRIIB.mFc did not increase survival or neuromuscular junction innervation in SOD1G93A transgenic mice. Pharmacologic treatment with ActRIIB.mFc was superior in all measurements to genetic deletion of myostatin in SOD1G93A transgenic mice. The improved function of SOD1G93A transgenic mice following treatment with ActRIIB.mFc is encouraging for the development of TGF-β pathway inhibitors to increase muscle strength in patients with ALS.

Original languageEnglish (US)
Pages (from-to)258-268
Number of pages11
JournalExperimental Neurology
Volume217
Issue number2
DOIs
StatePublished - Jun 2009

Fingerprint

Myostatin
Amyotrophic Lateral Sclerosis
Transgenic Mice
Muscle Strength
Animal Disease Models
Muscles
Neuromuscular Junction
Hand Strength
Therapeutics
Nervous System Diseases
Respiratory Insufficiency
Body Weight
Ligands
Survival
activin receptor type II-B
Growth

Keywords

  • Activin receptor
  • ALS
  • Muscle
  • Myostatin
  • SOD1
  • Treatment

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. / Morrison, Brett; Lachey, Jennifer L.; Warsing, Leigh C.; Ting, Beverlie L.; Pullen, Abigail E.; Underwood, Kathryn W.; Kumar, Ravindra; Sako, Dianne; Grinberg, Asya; Wong, Vicki; Colantuoni, Elizabeth Ann; Seehra, Jasbir S.; Wagner, Kathryn Rae.

In: Experimental Neurology, Vol. 217, No. 2, 06.2009, p. 258-268.

Research output: Contribution to journalArticle

Morrison, B, Lachey, JL, Warsing, LC, Ting, BL, Pullen, AE, Underwood, KW, Kumar, R, Sako, D, Grinberg, A, Wong, V, Colantuoni, EA, Seehra, JS & Wagner, KR 2009, 'A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis', Experimental Neurology, vol. 217, no. 2, pp. 258-268. https://doi.org/10.1016/j.expneurol.2009.02.017
Morrison, Brett ; Lachey, Jennifer L. ; Warsing, Leigh C. ; Ting, Beverlie L. ; Pullen, Abigail E. ; Underwood, Kathryn W. ; Kumar, Ravindra ; Sako, Dianne ; Grinberg, Asya ; Wong, Vicki ; Colantuoni, Elizabeth Ann ; Seehra, Jasbir S. ; Wagner, Kathryn Rae. / A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. In: Experimental Neurology. 2009 ; Vol. 217, No. 2. pp. 258-268.
@article{c674dd3ba4604883a3d3ea7d9cd8bada,
title = "A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis",
abstract = "Amyotrophic lateral sclerosis (ALS) is a neurologic disease characterized by progressive weakness that results in death within a few years of onset by respiratory failure. Myostatin is a member of the TGF-β superfamily that is predominantly expressed in muscle and acts as a negative regulator of muscle growth. Attenuating myostatin has previously been shown to produce increased muscle mass and strength in normal and disease animal models. In this study, a mouse model of ALS (SOD1G93A transgenic mice) was treated with a soluble activin receptor, type IIB (ActRIIB.mFc) which is a putative endogenous signaling receptor for myostatin in addition to other ligands of the TGF-β superfamily. ActRIIB.mFc treatment produces a delay in the onset of weakness, an increase in body weight and grip strength, and an enlargement of muscle size whether initiated pre-symptomatically or after symptom onset. Treatment with ActRIIB.mFc did not increase survival or neuromuscular junction innervation in SOD1G93A transgenic mice. Pharmacologic treatment with ActRIIB.mFc was superior in all measurements to genetic deletion of myostatin in SOD1G93A transgenic mice. The improved function of SOD1G93A transgenic mice following treatment with ActRIIB.mFc is encouraging for the development of TGF-β pathway inhibitors to increase muscle strength in patients with ALS.",
keywords = "Activin receptor, ALS, Muscle, Myostatin, SOD1, Treatment",
author = "Brett Morrison and Lachey, {Jennifer L.} and Warsing, {Leigh C.} and Ting, {Beverlie L.} and Pullen, {Abigail E.} and Underwood, {Kathryn W.} and Ravindra Kumar and Dianne Sako and Asya Grinberg and Vicki Wong and Colantuoni, {Elizabeth Ann} and Seehra, {Jasbir S.} and Wagner, {Kathryn Rae}",
year = "2009",
month = "6",
doi = "10.1016/j.expneurol.2009.02.017",
language = "English (US)",
volume = "217",
pages = "258--268",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis

AU - Morrison, Brett

AU - Lachey, Jennifer L.

AU - Warsing, Leigh C.

AU - Ting, Beverlie L.

AU - Pullen, Abigail E.

AU - Underwood, Kathryn W.

AU - Kumar, Ravindra

AU - Sako, Dianne

AU - Grinberg, Asya

AU - Wong, Vicki

AU - Colantuoni, Elizabeth Ann

AU - Seehra, Jasbir S.

AU - Wagner, Kathryn Rae

PY - 2009/6

Y1 - 2009/6

N2 - Amyotrophic lateral sclerosis (ALS) is a neurologic disease characterized by progressive weakness that results in death within a few years of onset by respiratory failure. Myostatin is a member of the TGF-β superfamily that is predominantly expressed in muscle and acts as a negative regulator of muscle growth. Attenuating myostatin has previously been shown to produce increased muscle mass and strength in normal and disease animal models. In this study, a mouse model of ALS (SOD1G93A transgenic mice) was treated with a soluble activin receptor, type IIB (ActRIIB.mFc) which is a putative endogenous signaling receptor for myostatin in addition to other ligands of the TGF-β superfamily. ActRIIB.mFc treatment produces a delay in the onset of weakness, an increase in body weight and grip strength, and an enlargement of muscle size whether initiated pre-symptomatically or after symptom onset. Treatment with ActRIIB.mFc did not increase survival or neuromuscular junction innervation in SOD1G93A transgenic mice. Pharmacologic treatment with ActRIIB.mFc was superior in all measurements to genetic deletion of myostatin in SOD1G93A transgenic mice. The improved function of SOD1G93A transgenic mice following treatment with ActRIIB.mFc is encouraging for the development of TGF-β pathway inhibitors to increase muscle strength in patients with ALS.

AB - Amyotrophic lateral sclerosis (ALS) is a neurologic disease characterized by progressive weakness that results in death within a few years of onset by respiratory failure. Myostatin is a member of the TGF-β superfamily that is predominantly expressed in muscle and acts as a negative regulator of muscle growth. Attenuating myostatin has previously been shown to produce increased muscle mass and strength in normal and disease animal models. In this study, a mouse model of ALS (SOD1G93A transgenic mice) was treated with a soluble activin receptor, type IIB (ActRIIB.mFc) which is a putative endogenous signaling receptor for myostatin in addition to other ligands of the TGF-β superfamily. ActRIIB.mFc treatment produces a delay in the onset of weakness, an increase in body weight and grip strength, and an enlargement of muscle size whether initiated pre-symptomatically or after symptom onset. Treatment with ActRIIB.mFc did not increase survival or neuromuscular junction innervation in SOD1G93A transgenic mice. Pharmacologic treatment with ActRIIB.mFc was superior in all measurements to genetic deletion of myostatin in SOD1G93A transgenic mice. The improved function of SOD1G93A transgenic mice following treatment with ActRIIB.mFc is encouraging for the development of TGF-β pathway inhibitors to increase muscle strength in patients with ALS.

KW - Activin receptor

KW - ALS

KW - Muscle

KW - Myostatin

KW - SOD1

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67349251521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349251521&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2009.02.017

DO - 10.1016/j.expneurol.2009.02.017

M3 - Article

VL - 217

SP - 258

EP - 268

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -